Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 13/20 | 0.42 |
| ▸ | SYK | P43405 | 3/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | IGF1R | P08069 | 1/20 | 0.37 |
| ▸ | FLT1 | P17948 | 1/20 | 0.36 |
| ▸ | FLT4 | P35916 | 1/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4283564 | 0.88 | CDK5 (0.50) | KDRFLT1CDK5 | |
| SCHEMBL4288146 | 0.82 | KDR (0.45) | KDRIGF1RFLT1FLT4 | |
| SCHEMBL4291792 | 0.80 | CDK5 (0.48) | KDREGFRFLT1CDK5 | |
| SCHEMBL4288896 | 0.77 | CDK5 (0.46) | KDRFLT1FLT4CDK5 | |
| SCHEMBL4284818 | 0.77 | SYK (0.45) | KDRSYKEGFRKCNH2SCN5A | |
| SCHEMBL4282699 | 0.75 | CDK5 (0.51) | KDREGFRFLT1CDK5 | |
| SCHEMBL4279484 | 0.74 | CDK5 (0.46) | KDRSYKEGFRKCNH2SCN5A | |
| SCHEMBL4288235 | 0.73 | CDK5 (0.45) | KDRFLT1FLT4CDK5 | |
| SCHEMBL4289751 | 0.72 | CDK5 (0.48) | KDREGFRFLT1CDK5 | |
| SCHEMBL4284798 | 0.71 | CDK5 (0.46) | KDREGFRFLT1CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149467-A1 | Tyrosine Kinase Inhibitors | MERCK & CO., INC. (US) | 2009-06-11 | — | — | US | claimed |
| US-20090149467-A1 | Tyrosine Kinase Inhibitors | MERCK & CO., INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-20090149467-A1 | Tyrosine Kinase Inhibitors | MERCK & CO., INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-20090149467-A1 | Tyrosine Kinase Inhibitors | MERCK & CO., INC. (US) | 2009-06-11 | — | — | US | disclosed |
| EP-1934200-A1 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007035309-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149467-A1 | Tyrosine Kinase Inhibitors | ABL1, MET, ERBB2 | KDR 165/4885SYK 86/4885EGFR 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.